The marine-derived antimicrobial peptide Ajapocin killed pathogenic Vibrio bacteria at concentrations comparable to clinical antibiotics, healed infected wounds in mice, and showed no organ toxicity after a week of treatment.
MIC 6-12 μMAjapocin's antibacterial potency against pathogenic Vibrio species — comparable to the clinical antibiotic Polymyxin B — with demonstrated efficacy in both zebrafish and mouse infection models
What the researchers found
Ajapocin showed potent activity against V. parahaemolyticus and V. vulnificus with MICs of 6-12 μM — comparable to Polymyxin B. In vivo efficacy was demonstrated in both zebrafish (single dose, 1 mg/mL) and mouse models (multiple doses reduced bacterial burden and accelerated wound healing). No cytotoxicity was observed in ZF4 or HaCaT cells up to 32 μM. One week of daily intraperitoneal injection caused no hepatic or renal toxicity confirmed by histopathology and blood chemistry.
The mechanism involves targeting negatively charged bacterial membrane components, enhancing membrane permeation, inducing depolarization, and causing membrane destruction — a membranolytic pattern that is difficult for bacteria to develop resistance against.
Why it matters
Vibrio infections are a growing public health concern: they cause severe seafood-borne illness and can create life-threatening wound infections, particularly in people with liver disease or immune compromise. With antibiotic resistance increasing, antimicrobial peptides like Ajapocin offer an alternative that bacteria are unlikely to develop resistance against, while also addressing aquaculture safety where antibiotic overuse is a major concern.
How the study worked
Ajapocin was identified through sequence optimization of a marine-source peptide. In vitro activity was measured via MIC determination against V. parahaemolyticus and V. vulnificus, compared with Polymyxin B. In vivo testing used a zebrafish-Vibrio infection model and a mouse V. vulnificus-infected skin wound model. Safety was assessed via cell viability assays (ZF4, HaCaT cells) and 1-week intraperitoneal injection toxicity study with histopathology and blood chemistry. Mechanistic studies examined membrane interaction, permeation, depolarization, and damage.
What this study cannot tell us
The mouse wound model used topical application, but systemic treatment for disseminated Vibrio infections was not tested. The 1-week toxicity study is short for assessing chronic safety. Only Vibrio species were tested — the spectrum of activity against other pathogens is unknown. The transition from animal models to human clinical use requires extensive development including pharmacokinetics, formulation optimization, and regulatory approval.
How to read the evidence
This is a preclinical study with comprehensive in vitro characterization, two different in vivo animal models (zebrafish and mouse), and safety assessment including histopathology. The multi-model approach provides strong preclinical evidence, though human clinical translation requires further development.
When this study was published
Published in 2026, this is cutting-edge research on a newly discovered antimicrobial peptide with immediate relevance to both aquaculture safety and human health.
The bigger picture
Marine organisms are a rich source of antimicrobial peptides that have evolved to survive in microbe-rich aquatic environments. Ajapocin adds to the growing library of marine-derived AMPs being developed as alternatives to conventional antibiotics. Its dual relevance to both aquaculture (preventing Vibrio outbreaks in farmed fish) and human medicine (treating Vibrio wound infections) makes it particularly promising for One Health applications.
Questions still open
- Does Ajapocin maintain efficacy against antibiotic-resistant Vibrio strains?
- Could Ajapocin be formulated for use in aquaculture feed to prevent Vibrio outbreaks in fish farms?
- What is Ajapocin's spectrum of activity beyond Vibrio — is it effective against other Gram-negative pathogens?
Common questions
What makes antimicrobial peptides different from regular antibiotics?
Why are Vibrio bacteria dangerous?
Read the original research
A Vibrio-susceptibility class of antimicrobial peptide Ajapocin via membranolytic pattern to combat "non-cholera" pathogens in vivo infection models.
Biochemical pharmacology, 247, 117766
Citation
Wang, Xiaofei; Hong, Xiao; Liu, Wanting; Xu, Yujun; Chen, Roushi; Chen, Fangyi; Wang, Ke-Jian; Wang, Luxi. (2026). A Vibrio-susceptibility class of antimicrobial peptide Ajapocin via membranolytic pattern to combat "non-cholera" pathogens in vivo infection models.. Biochemical pharmacology, 247, 117766. https://doi.org/10.1016/j.bcp.2026.117766